Enhancing Efficacy of a Brief Obesity and Eating Disorder Prevention Program: Long-Term Results from an Experimental Therapeutics Trial
Nutrients · 2023
DOI: 10.3390/nu15041008 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2023. Verfasst von Eric Stice und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Road Stanford, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: Overweight, Feeding and Eating Disorders. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, National Institute of Child Health and Human Development (NICHD).
Abstract (Originalsprache)
Objective
Test whether the efficacy of Project Health, an obesity/eating disorder prevention program, is improved by delivering it in single-sex groups and adding food response inhibition and attention training.
Method
High-risk young adults (N = 261; M age = 19.3, 74% female) were randomized to (1) single-sex or (2) mixed-sex groups that completed food response inhibition and attention training or (3) single-sex or (4) mixed-sex groups that completed sham training with nonfood images in a 2 × 2 factorial design.
Results
There was a significant sex-composition by training-type by time interaction; participants who completed single- or mixed-sex Project Health groups plus food response and attention training showed significant reductions in body fat over a 2-year follow-up, though this effect was more rapid and persistent in single-sex groups, whereas those who completed single- or mixed-sex Project Health groups plus sham training did not show body fat change. However, there were no differences in overweight/obesity onset over the follow-up. The manipulated factors did not affect eating disorder symptoms or eating disorder onset, but there was a significant reduction in symptoms across the conditions (within-condition d = −0.58), converging with prior evidence that Project Health produced larger reductions in symptoms (within-condition d = −0.48) than educational control participants. Average eating disorder onset over the 2-year follow-up (6.4%) was similar to that observed in Project Health in a past trial (4.5%).
Conclusions
Given that Project Health significantly reduced future onset of overweight/obesity in a prior trial and the present trial found that body fat loss effects were significantly greater when implemented in single-sex groups and paired with food response and attention training, there might be value in broadly implementing this combined intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Road Stanford, Stanford, CA 94305, USA.
- Oregon Research Institute, Springfield, OR 97477, USA.
- Department of Psychology, Drexel University, Philadelphia, PA 19104, USA.
- Department of Statistics, Saint Michaels College, Colchester, VT 05439, USA.
ORCID-Profile: Paul Rohde
Förderung
- NICHD NIH HHS
- National Institute of Child Health and Human Development (NICHD)
Zitieren
APA
Stice, E., Rohde, P., Butryn, M. L., Desjardins, C., & Shaw, H. (2023). Enhancing Efficacy of a Brief Obesity and Eating Disorder Prevention Program: Long-Term Results from an Experimental Therapeutics Trial. Nutrients. https://doi.org/10.3390/nu15041008
Vancouver
Stice E, Rohde P, Butryn ML, Desjardins C, Shaw H. Enhancing Efficacy of a Brief Obesity and Eating Disorder Prevention Program: Long-Term Results from an Experimental Therapeutics Trial. Nutrients. 2023. doi:10.3390/nu15041008
BibTeX
@article{Stice2023,
author = {Stice, Eric and Rohde, Paul and Butryn, Meghan L and Desjardins, Christopher and Shaw, Heather},
title = {Enhancing Efficacy of a Brief Obesity and Eating Disorder Prevention Program: Long-Term Results from an Experimental Therapeutics Trial},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15041008}
}
EUVIMED